Nuvectis Pharma, Inc. NVCT 深 滬
已收盤 09-20 16:00:00 美东时间
6.50
-0.250
-3.70%
華盛通- 最 高6.86
- 今 開6.71
- 成交量 14.43万股
- 最 低 6.46
- 昨 收 6.75
- 總市值 1.12亿
- 52周最高 14.4099
- 市盈率 靜 --
- 換手率 0.84%
- 52周最低 5.85
- 委 比 63.93%
- 總股本 1723.13万
- 歷史最高 20.92
- 量 比 1.21
- 振 幅 5.93%
- 歷史最低 3.08
- 每 手 1
- 風險率 1.71%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Nuvectis gains on FDA’s orphan drug designation for cancer therapy
Nuvectis Pharma (NASDAQ:NVCT) added ~7% in the premarket on Thursday after the cancer drug developer announced that the U.S. FDA offered its orphan drug designation for NXP800, one of its clinical-sta...
08-29 21:23
快讯 | Nuvectis Pharma股票在FDA对卵巢癌治疗的“孤儿药”标签上市前上涨7.6%
Nuvectis Pharma Shares up 7.6% Premarket on FDA's 'orphan Drug' Tag for Ovarian...
08-29 20:11
Nuvectis Pharma reports Q2 results
Nuvectis Pharma press release (NASDAQ:NVCT): Q2 Interest income was $0.2 million for the three months ended June 30, 2024, compared to $0.1 million for the three months ended June 30, 2023, an increas...
08-06 21:58
Nuvectis Pharma Q2 EPS $(0.26), Inline
Nuvectis Pharma (NASDAQ:NVCT) reported quarterly losses of $(0.26) per share which met the analyst consensus estimate. This is a 31.58 percent increase over losses of $(0.38) per share from the same period last year.
08-06 21:44
快讯 | Nuvectis Pharma Q2营业收入美元指数-464.3万
Nuvectis Pharma Q2 Operating Income USD -4.643 Million
08-06 20:29
快讯 | Nuvectis Pharma，Inc.报告了2024年第二季度的财务业绩和业务亮点
Nuvectis Pharma, Inc. Reports Second Quarter 2024 Financial Results and Busines...
08-06 20:29
Nuvectis Pharma Q1 EPS of -$0.25
Nuvectis Pharma press release (NASDAQ:NVCT): Q1 EPS of -$0.25. Cash, and cash equivalents were $19.5 million as of March 31, 2024, compared to $19.1 million as of December 31, 2023. More on Nuvectis ...
05-07 22:35
Nuvectis Pharma's NXP900 Demonstrates Robust Activity In Non-Small Cell Lung Cancer Cell Lines
Highly Synergistic Antiproliferative Activity in EGFR-resistant Cells in Combination with Osimertinib, the Active Ingredient in TagrissoTMSingle Agent Antiproliferative Activity in Cells Resistant to Alectinib, the
04-08 20:41
Recap: Nuvectis Pharma Q3 Earnings
Nuvectis Pharma (NASDAQ:NVCT) reported its Q3 earnings results on Wednesday, No...
2023-11-08 21:10
Nuvectis Pharma Analyst Ratings
What is the target price for Nuvectis Pharma (NVCT)? The latest price target...
2023-09-15 18:10
